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ABSTRACT
We investigated in a preclinical canine model of hematopoietic cell transplantation (HCT) whether preemptive
donor lymphocyte infusion (DLI) given 1 month after HCT could prevent late graft rejection that was the rule
in historical dogs given suboptimal conditioning with 1 Gy of total body irradiation (TBI) before and
immunosuppression with cyclosporine (CSP) and either mycophenolate mofetil (MMF; n  6) or rapamycin
(n  5) after dog leukocyte antigen (DLA)-identical marrow transplantation. Nine dogs given DLA-identical
marrow after 1 Gy of TBI followed by postgrafting MMF and CSP were studied. A single DLI was given 28-36
days after HCT, either with (n  5) or without (n  4) preceding treatment with the immunosuppressive drug
pentostatin. Two of the 4 dogs given DLI only maintained stable mixed donor–host chimera beyond 30 weeks
after HCT, whereas 2 rejected their grafts, on weeks 10 and 15 after HCT. One of the 5 dogs given pentostatin
before DLI maintained a stable mixed donor–host chimera beyond 30 weeks, whereas 4 rejected their grafts,
at weeks 8, 12, 12, and 16 after HCT. The 30-week probability of stable mixed chimerism was 33% among dogs
given DLI, versus 0% among 11 historical dogs (P  .003). In conclusion, DLI was only moderately effective
in preventing graft rejection in this model. Additional immunosuppression with pentostatin did not improve
that outcome. The model might be useful in developing potential strategies aimed at preventing graft rejection
in patients with low donor chimerism levels.
© 2006 American Society for Blood and Marrow Transplantation
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Nonfatal late rejections of hematopoietic grafts
ay occur after nonmyeloablative or reduced-inten-
ity conditioning regimens, particularly in patients
ith chronic myeloid leukemia or myelodysplastic
yndromes given grafts from unrelated donors [1-4].
ow levels (50%) of donor chimerism in T cells
5,6] and natural killer (NK) cells [1,6,7] on days 14
nd 28 after transplantation are predictive of a greater
isk of graft rejection. Speciﬁcally, patients with donor
K- and T-cell chimerism levels 50% on day 14 pfter hematopoietic cell transplantation (HCT) had a
0% probability of graft rejection [6]. Assessing the
fﬁcacy of strategies aimed at preventing graft rejec-
ion in patients with low-donor chimerism levels has
roven difﬁcult, because only approximately half of
he patients with low donor chimerism levels eventu-
lly experience graft rejection; this emphasizes the
eed for a good animal model.
We have previously shown that 92% and 86% of
ogs given dog leukocyte antigen (DLA)-identical
arrow after 2 Gy of total body irradiation (TBI) and
ostgrafting immunosuppression with cyclosporine
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F. Baron et al.814CSP) plus mycophenolate mofetil (MMF) [8], or with
SP plus rapamycin [9], achieved sustained mixed
onor–host chimerism. This approach has been suc-
essfully translated to treat human patients with he-
atologic malignancies or primary immunodeﬁciency
iseases [2,5,10], demonstrating the clinical relevance
f the canine model. However, when the TBI dose was
educed to 1 Gy, graft rejection was observed in 6 of 6
ogs given CSP and MMF [8] and in 5 of 5 dogs given
SP and rapamycin [9]. Graft rejections observed after 1
y of TBI in this model were consistent with host-
ersus-graft reactions rather than with a lack of marrow
pace [11-13], as reviewed by Baron and Storb [10].
Here we investigated whether a preemptive donor
ymphocyte infusion (DLI) given 1 month after HCT
ould prevent late graft rejection in dogs given 1 Gy of
BI before and MMF and CSP after DLA-identical
arrow transplantation.
ATERIALS AND METHODS
Nine donor/recipient pairs (8 pairs of littermates
nd 1 pair of siblings), 7-10 (median 9) months old,
nd raised at the Fred Hutchinson Cancer Research
enter, were DLA-identical on the basis of matching
or highly polymorphic DLA-associated class I and
lass II microsatellite marker polymorphisms and
LA-DRB1 sequencing [9,14,15].
able 1. Duration of Mixed Donor–Host Chimerism in Dogs Given M
Study Group) or Not Followed (Historical Group) by Preemptive DLI G
Dog No.
Nucleated
Marrow Cells
(108/kg) Pentostatin?
DLI: T C
(day a
istorical group
E165 4.0 No
E166 4.0 No
E202 4.1 No
E204 4.0 No
E227 4.0 No
E228 4.0 No
G092† 3.6 No
G111† 6.3 No
G151† 3.7 No
G156† 3.8 No
G167† 4.2 No
tudy group
G335 6.3 No 1
G376 2.4 No 2
G329 2.4 No 2
G444 5.4 No 2
G468 4.0 4 mg/m2 1
G509 3.8 4 mg/m2 1
G541 3.5 4 mg/m2 1
G565 2.8 3  4 mg/m2 1
G582 5.4 3  4 mg/m2 1
Eight weeks in the granulocyte fraction.
These dogs were given CSP plus rapamycin instead of CSP plus MMF aRecipients were administered 1 Gy of TBI deliv-
red at 7 cGy/min from a linear accelerator (CLINAC
; Varian, Palo Alto, CA). Marrow cells were aspirated
rom donors under general anesthesia through long
eedles inserted into the humeri. Marrow grafts con-
aining 2.4  108-6.3  108 (median, 3.8  108) total
ucleated cells per kg of the recipient were given
hrough intravenous (IV) infusion within hours of TBI.
mmunosuppression consisted of MMF, 10 mg/kg twice
day injected subcutaneously, from days 0-27, and CSP,
5 mg/kg twice a day orally, starting on day 1. CSP
as discontinued either 1 day before DLI (for dogs
ot given pentostatin) or 1 day before pentostatin.
onor peripheral blood mononuclear cells (PBMCs)
ere collected 28-38 days (median, 33 days) after
CT by a COBE Spectra 6-cell separator (Grambo,
akewood, CO) and were given through IV infusion
DLI) within hours of collection. Five dogs received
osttransplantation pentostatin, 4 mg/m2/day IV for
ither 1 day (2 days before DLI; n 3) or 3 days (days
4 to 2 before DLI; n  2) (Table 1). Pentostatin
as given as an IV bolus injection after infusion of 500
L of saline solution, as reported previously [16].
retransplantation pentostatin (either 3 4 mg/m2 or
 4 mg/m2 IV) administration was previously shown
o prolong DLA-identical marrow engraftment in
ogs given 1 Gy of TBI and posttransplantation MMF
lus CSP [16]. The number of T cells in the DLIs was
Grafts from DLA-Identical Donors after 1 Gy TBI Followed
Month after Transplantation
108/kg
CT)
Percent Donor
Chimerism in PBMC
before DLI
Duration of Mixed
Chimerism, Among PBMC,
in Weeks (final % of donor
chimerism in PBMC)
/ 12 (0)
/ 10 (0)
/ 3 (0)
/ 3 (0)
/ 10 (0)
/ 10 (0)
/ 9 (0)
/ 11 (0)
/ 3 (0)
/ 9 (0)
/ 9 (0)
40.0 >32 (46.5)
8.8 15 (0)
7.7 10 (0)
29.3 >35 (5.0)
23.1 16 (0)
38.6 12 (0)
16.2 >33 (15.8)
9.9 7* (0)
14.8 12 (0)arrow
iven 1
ells 
fter H
No
No
No
No
No
No
No
No
No
No
No
.0 (36)
.0 (28)
.3 (39)
.6 (29)
.6 (38)
.6 (30)
.1 (30)
.7 (33)
.4 (33)s postgrafting immunosuppression.
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DLI after 1 Gy TBI and DLA-Identical BMT 815ssessed by ﬂow cytometry using a monoclonal anti-
ody directed against canine CD3 (CA17.6F9, IgG2b),
s reported previously [15]; levels ranged from 1.0 108
o 2.6  108 T cells/kg (Table 1).
The presence of donor cells in PBMCs and gran-
locytes after HCT was assessed by ﬂuorescent vari-
ble number tandem repeat polymerase chain reaction
ssays using an ABI Prism 310 Genetic Analyzer and
ene Scan 3.1 software (Applied BioSystems, Foster
ity, CA) [15]. The endpoint of the study was stable
ixed donor–host hematopoietic chimerism beyond
0 weeks after HCT.
Data from dogs in this study were compared with
hose from a historical group of 11 dogs given DLA-
dentical marrow grafts after 1 Gy TBI and receiving
ostgrafting immunosuppression with either CSP and
MF or CSP and rapamycin [8,9].
The study was approved by the Institutional Ani-
al Care and Use Committee at the Fred Hutchinson
ancer Research Center.
ESULTS
ngraftment, DLI, and Graft Rejection
Initial donor engraftment was documented in all
ogs. Two of the 4 dogs given DLI only maintained
table mixed donor–host chimeras beyond 30 weeks
fter HCT, whereas 2 rejected their grafts, on weeks
0 and 15 (Table 1). We then investigated in 5 dogs
hether host immunosuppression with pentostatin
efore DLI could allay the pending rejection by in-
reasing the efﬁcacy of DLI. One of the 5 dogs given
entostatin before DLI maintained a stable mixed
onor–host chimera beyond 30 weeks, whereas the
ther 4 (including the 2 dogs given 3 doses of pen-
ostatin) rejected their grafts, on weeks 8, 12, 12, and
6 after HCT (Table 1). Donor PBMC chimerism
evels before DLI were 28.5%  11.9% in the 3 dogs
ith sustained engraftment, compared with 17.2% 
1.9% in the 6 dogs with graft rejection (P  not
igniﬁcant [NS]). The absolute lymphocyte counts
efore DLI were 1203  741 in the 3 dogs with
ustained engraftment, versus 1990  712 in the 6
ogs with graft rejection (P  NS).
oxicity
Hematologic toxicities were generally mild
Figure 1). Median platelet, neutrophil, and lympho-
yte nadirs were 32,000, 2077, and 396 cells/L, re-
pectively. Changes in lymphocyte counts were not
tatistically different between the dogs given and not
iven pentostatin (data not shown).
The main nonhematologic toxicity was gastroin-
estinal; effects included anorexia, diarrhea, and mod-
rate weight loss, most likely due to MMF. In addi-
ion, 1 animal (G565) developed intussusception atay 26 after HCT that was successfully removed sur-
ically. Intussusception is associated with the use of
SP in dogs.
igure 1. (A) Median peripheral blood changes in 9 dogs given 1
y of TBI before and MMF/CSP plus DLI (with or without
receding pentostatin) after marrow transplantation from DLA-
dentical donors; (B) PBMC chimerism in 4 dogs given 1 Gy of TBI
efore and MMF/CSP plus DLI after marrow transplantation from
LA-identical donors; (C) PBMC chimerism in 5 dogs given 1 Gy
f TBI before and MMF/CSP, pentostatin plus DLI after marrow
ransplantation from DLA-identical donors.Pentostatin and DLI were well tolerated. Graft-
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F. Baron et al.816ersus-host disease (GVHD) was not observed in any
og.
omparison of Graft Rejection
ith Historical Dogs
The numbers of nucleated marrow cells transplanted
n present (2.4  108/kg–6.3  108/kg [median, 3.8 
08/kg]) and historical dogs (3.6  108/kg-6.3 
08/kg [median, 4.0  108/kg]) were comparable (P 
3). There was a statistical trend for decreased risk of
ejection in dogs receiving higher numbers of nucle-
ted marrow cells (analyzed as a continuous variable; P
.07). The 30-week probability of sustained donor
ngraftment was 33% in dogs given DLI, versus 0% in
istorical dogs (P  .003 in univariate analysis and P
.002 after adjusting for the number of nucleated
arrow cells transplanted). After excluding the 5 his-
orical dogs given CSP plus rapamycin as postgrafting
mmunosuppression, the P values were .03 and .02,
espectively.
ISCUSSION
In contrast to cancer patients undergoing nonmy-
loablative HCT, who most often received various
mount of cytotoxic therapy before nonmyeloablative
onditioning, dogs included in the current study did
ot receive any chemotherapy before conditioning to
CT, making them an ideal model for assessing ways
o further improve donor engraftment. In a previous
tudy, we observed stable mixed donor–host chimer-
sm in 5 of 8 dogs given 1 Gy of TBI followed by
LA-identical marrow plus granulocyte-colony-stim-
lating factor–mobilized PBMC grafts (containing 1.9
0.5  108 T cells/kg), and in 1 of 7 dogs given 1 Gy
f TBI followed by marrow plus CD3-depleted G-
BMCs [13], suggesting that the addition of donor T
ells to the marrow grafts promoted sustained engraft-
ent. Here we investigated whether infusion of addi-
ional donor T cells as late as 5 weeks after HCT, after
iscontinuation of immunosuppression, would pro-
ote stable engraftment in dogs given marrow grafts
fter 1 Gy of TBI.
Given in this manner, DLIs prevented graft rejec-
ion in only 2 of 4 dogs, suggesting that host T cells in
he other 2 dogs were already sensitized against donor
inor histocompatibility antigens when immunosup-
ression was discontinued and were capable of de-
troying both the marrow graft and the infused donor
ymphocytes. The lack of uniform efﬁcacy of DLI in
he current canine model is consistent with observa-
ions made in human patients, where DLIs were often
neffective in preventing graft rejection in settings of
ow donor chimerism levels [17,18].
We next evaluated whether pentostatin, a potent
mmunosuppressive drug in both humans and dogs D16,19], could reduce the number of sensitized host
ymphocytes sufﬁciently to set the stage for DLI to
romote stable donor engraftment. This strategy met
ith little success, because only 1 of 5 dogs achieved
table mixed chimerism. Perhaps pentostatin affected
ot only sensitized host T cells, but also regulatory T
ells [20], which have been implicated in the mainte-
ance of stable mixed chimerism after nonmyeloabla-
ive conditioning [21,22].
Pentostatin and DLI appeared to be safe, and no
cute GVHD was seen in dogs that achieved sustained
ngraftment. This was most likely related to the mixed
onor–host T-cell chimerism with relatively low do-
or contributions, a condition associated with a low
ncidence of GVHD [6].
In conclusion, DLI was only moderately effec-
ive in allaying graft rejection in this model, even
hen preceded by host immunosuppression with
entostatin. The canine model might be useful in
eveloping better strategies for preventing graft re-
ection in patients with low donor chimerism levels.
hese strategies should be aimed at speciﬁcally tar-
eting activated (sensitized) T cells, without affect-
ng regulatory T cells. Potential candidates include
ortezomib, recently shown to speciﬁcally inhibit
ctivated T cells [23], and radionuclide-conjugated
onoclonal antibodies targeting the CD70 antigen
24].
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